BioCentury | Sep 16, 2020
Deals

A deal for Grail could be Illumina’s next shot at diversifying

...the $6 billion valuation Grail Inc. garnered from its series D round in May, according to a Bloomberg article...
BioCentury | Aug 24, 2020
Regulation

Ex-FDA officials: EUA may be merited, but FDA put politics ahead of science

...for public health at the Johns Hopkins Bloomberg...
BioCentury | Aug 17, 2020
Deals

Via $3.4B Principia takeout, Sanofi can explore potential of Btk inhibitor beyond MS

...biotech acquisitions, although Principia’s shares had run up considerably in recent weeks, particularly after a Bloomberg...
BioCentury | Jun 8, 2020
Deals

Why an AZ-Gilead megadeal doesn’t make sense for investors

...companies should hope the chatter amounts to nothing. Both companies declined to comment on a Bloomberg...
BioCentury | May 14, 2020
Regulation

Manufacturing limits spark fears of COVID-19 vaccine nationalism

...doesn’t do that is likely to be accused of being irresponsible by its own population.” Bloomberg...
BioCentury | Apr 16, 2020
Deals

Arcus mum on report of Gilead’s approach

...gained $14.01 (90%) to $29.50, adding more than $640 million in market cap, after a Bloomberg...
BioCentury | Apr 15, 2020
Product Development

Let’s improve molecular diagnostics reimbursement for the sake of public health

...NYSE:LLY) and a senior associate in the Department of Health Policy and Management in the Bloomberg...
BioCentury | Feb 29, 2020
Deals

Is Forty Seven on Gilead’s ‘urgent’ shopping list?

...a three-month run that has seen its stock rise 10-fold over its 2019 low. The Bloomberg...
BioCentury | Feb 26, 2020
Product Development

Feb. 25 Quick Takes: Vanda’s Phase III miss; plus Iovance; 1st-twoXAR; app for AFib, stroke; ICER-Aetion; new-look Purple Book, and more

...sale Iovance Biotherapeutics Inc. (NASDAQ:IOVA) gained $6.77 (27%) to $31.46 Tuesday after a report in Bloomberg...
BioCentury | Jan 27, 2020
Financial News

Bloomberg calls for single 20-year patent term for pharmaceuticals

...Democratic presidential candidate Mike Bloomberg released a drug price plan Monday that includes a proposal to...
...that includes a proposal to limit patent protection for drug to a single 20-year patent. Bloomberg...
...Bloomberg also advocated “eliminating drug company payoffs to Pharmacy Benefit Managers.” Steve Usdin, Washington Editor Drug pricing Mike Bloomberg...
Items per page:
1 - 10 of 100
BioCentury | Sep 16, 2020
Deals

A deal for Grail could be Illumina’s next shot at diversifying

...the $6 billion valuation Grail Inc. garnered from its series D round in May, according to a Bloomberg article...
BioCentury | Aug 24, 2020
Regulation

Ex-FDA officials: EUA may be merited, but FDA put politics ahead of science

...for public health at the Johns Hopkins Bloomberg...
BioCentury | Aug 17, 2020
Deals

Via $3.4B Principia takeout, Sanofi can explore potential of Btk inhibitor beyond MS

...biotech acquisitions, although Principia’s shares had run up considerably in recent weeks, particularly after a Bloomberg...
BioCentury | Jun 8, 2020
Deals

Why an AZ-Gilead megadeal doesn’t make sense for investors

...companies should hope the chatter amounts to nothing. Both companies declined to comment on a Bloomberg...
BioCentury | May 14, 2020
Regulation

Manufacturing limits spark fears of COVID-19 vaccine nationalism

...doesn’t do that is likely to be accused of being irresponsible by its own population.” Bloomberg...
BioCentury | Apr 16, 2020
Deals

Arcus mum on report of Gilead’s approach

...gained $14.01 (90%) to $29.50, adding more than $640 million in market cap, after a Bloomberg...
BioCentury | Apr 15, 2020
Product Development

Let’s improve molecular diagnostics reimbursement for the sake of public health

...NYSE:LLY) and a senior associate in the Department of Health Policy and Management in the Bloomberg...
BioCentury | Feb 29, 2020
Deals

Is Forty Seven on Gilead’s ‘urgent’ shopping list?

...a three-month run that has seen its stock rise 10-fold over its 2019 low. The Bloomberg...
BioCentury | Feb 26, 2020
Product Development

Feb. 25 Quick Takes: Vanda’s Phase III miss; plus Iovance; 1st-twoXAR; app for AFib, stroke; ICER-Aetion; new-look Purple Book, and more

...sale Iovance Biotherapeutics Inc. (NASDAQ:IOVA) gained $6.77 (27%) to $31.46 Tuesday after a report in Bloomberg...
BioCentury | Jan 27, 2020
Financial News

Bloomberg calls for single 20-year patent term for pharmaceuticals

...Democratic presidential candidate Mike Bloomberg released a drug price plan Monday that includes a proposal to...
...that includes a proposal to limit patent protection for drug to a single 20-year patent. Bloomberg...
...Bloomberg also advocated “eliminating drug company payoffs to Pharmacy Benefit Managers.” Steve Usdin, Washington Editor Drug pricing Mike Bloomberg...
Items per page:
1 - 10 of 100